• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

An overview of the status of acellular pertussis vaccines in practice.

作者信息

Lopez A L, Blumberg D A

机构信息

Department of Paediatric Infectious Diseases, University of the Philippines, Philippine General Hospital, Manila, Philippines.

出版信息

Drugs. 1997 Aug;54(2):189-96. doi: 10.2165/00003495-199754020-00001.

DOI:10.2165/00003495-199754020-00001
PMID:9257078
Abstract

Infection with Bordetella pertussis continues to result in widespread morbidity and mortality. Although whole cell pertussis vaccines are effective in controlling pertussis, concerns relating to adverse effects following vaccination have led to the development of a new generation of pertussis vaccines. Acellular pertussis vaccines have decreased endotoxin content and are less reactogenic than whole cell vaccines. The composition of acellular pertussis vaccines varies, resulting in differing immunogenicity. Recent studies have demonstrated that these vaccines, in general, have an efficacy similar to that of whole cell vaccines. The development of acellular pertussis vaccines is an advance that should result in less discomfort from vaccination and the potential for increased vaccine usage, resulting in the possible elimination of this disease.

摘要

相似文献

1
An overview of the status of acellular pertussis vaccines in practice.
Drugs. 1997 Aug;54(2):189-96. doi: 10.2165/00003495-199754020-00001.
2
A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.两种无细胞百日咳疫苗和一种全细胞百日咳疫苗的对照试验。百日咳项目工作组。
N Engl J Med. 1996 Feb 8;334(6):341-8. doi: 10.1056/NEJM199602083340601.
3
Immunogenicity of a five-component acellular pertussis vaccine in infants and young children.
Arch Pediatr Adolesc Med. 1994 May;148(5):495-502. doi: 10.1001/archpedi.1994.02170050053010.
4
A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.一项关于双组分无细胞、五组分无细胞和全细胞百日咳疫苗的对照试验。
N Engl J Med. 1996 Feb 8;334(6):349-55. doi: 10.1056/NEJM199602083340602.
5
Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.家庭接触百日咳博德特氏菌后与保护作用相关的抗百日咳抗体水平。
Vaccine. 1998 Dec;16(20):1907-16. doi: 10.1016/s0264-410x(98)00227-8.
6
Japanese clinical trials with Takeda acellular pertussis vaccine.武田无细胞百日咳疫苗的日本临床试验。
Tokai J Exp Clin Med. 1988;13 Suppl:15-9.
7
Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.无细胞疫苗可在接受百日咳初次疫苗接种的婴儿中诱导针对百日咳博德特氏菌抗原的细胞介导免疫。
Dev Biol Stand. 1997;89:315-20.
8
Immune responses to pertussis vaccines concurrently administered with viral vaccines.对与病毒疫苗同时接种的百日咳疫苗的免疫反应。
Ann N Y Acad Sci. 1995 May 31;754:89-96. doi: 10.1111/j.1749-6632.1995.tb44441.x.
9
Comparison of 13 acellular pertussis vaccines: overview and serologic response.13种无细胞百日咳疫苗的比较:概述与血清学反应
Pediatrics. 1995 Sep;96(3 Pt 2):548-57.
10
Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.构建并评价百日咳鲍特菌活疫苗株 BPZE1 生产 Fim3 的效果。
Vaccine. 2018 Mar 7;36(11):1345-1352. doi: 10.1016/j.vaccine.2018.02.017. Epub 2018 Feb 9.

引用本文的文献

1
Which strategy for pertussis vaccination today?如今百日咳疫苗接种采用哪种策略?
Paediatr Drugs. 2002;4(5):299-313. doi: 10.2165/00128072-200204050-00003.
2
Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.吸附白喉-破伤风-无细胞百日咳疫苗(Triacelluvax;DTaP3-CB):其用于预防百日咳博德特氏菌感染的综述
Paediatr Drugs. 2000 Mar-Apr;2(2):139-59. doi: 10.2165/00148581-200002020-00007.

本文引用的文献

1
FDA approval of a second acellular pertussis vaccine for use among infants and young children.
MMWR Morb Mortal Wkly Rep. 1997 Feb 7;46(5):110-1.
2
FDA approval of a Haemophilus b Conjugate Vaccine combined by reconstitution with an acellular pertussis vaccine.美国食品药品监督管理局批准一种通过与无细胞百日咳疫苗复溶组合而成的b型流感嗜血杆菌结合疫苗。
MMWR Morb Mortal Wkly Rep. 1996 Nov 15;45(45):993-5.
3
Food and Drug Administration approval of an acellular pertussis vaccine for the initial four doses of the diphtheria, tetanus, and pertussis vaccination series.美国食品药品监督管理局批准一种无细胞百日咳疫苗用于白喉、破伤风和百日咳疫苗接种系列的前四剂。
MMWR Morb Mortal Wkly Rep. 1996 Aug 9;45(31):676-7.
4
The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1-65 years.
J Infect Dis. 1996 May;173(5):1256-9. doi: 10.1093/infdis/173.5.1256.
5
Household contact study of Bordetella pertussis infections.百日咳博德特氏菌感染的家庭接触者研究。
Clin Infect Dis. 1995 Nov;21(5):1211-9. doi: 10.1093/clinids/21.5.1211.
6
Acellular pertussis vaccines for infants.用于婴儿的无细胞百日咳疫苗。
N Engl J Med. 1996 Feb 8;334(6):391-2. doi: 10.1056/NEJM199602083340609.
7
A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.一项关于双组分无细胞、五组分无细胞和全细胞百日咳疫苗的对照试验。
N Engl J Med. 1996 Feb 8;334(6):349-55. doi: 10.1056/NEJM199602083340602.
8
A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.两种无细胞百日咳疫苗和一种全细胞百日咳疫苗的对照试验。百日咳项目工作组。
N Engl J Med. 1996 Feb 8;334(6):341-8. doi: 10.1056/NEJM199602083340601.
9
Acellular pertussis vaccines--a solution to the pertussis problem.
J Infect Dis. 1993 Jul;168(1):21-4. doi: 10.1093/infdis/168.1.21.
10
Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying.与白喉-破伤风-百日咳疫苗相关的严重反应:对出现癫痫、低张-低反应发作、高热和持续性哭闹的儿童的详细研究。
Pediatrics. 1993 Jun;91(6):1158-65.